Printer Friendly

MEDIMMUNE'S RESPIVIR(TM) TO BE REVIEWED BY FDA ADVISORY COMMITTEE

 GAITHERSBURG. Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) today announced that the Blood Products Advisory Committee for the United States Food and Drug Administration (FDA) will meet on the morning of Sept. 23, 1993 to review the application for marketing approval for Respivir(TM). Respivir(TM) is a polyclonal antibody product developed by MedImmune for the prevention of respiratory syncytial virus (RSV) infection in certain high risk infants. RSV is the leading cause of pneumonia and bronchiolitis in infants.
 MedImmune, Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's corporate headquarters are in Gaithersburg.
 -0- 8/23/93
 /CONTACT: David M. Mott, vice president-development and planning, 301-417-0770, or Anthony J. Russo or Rhonda Chiger of Noonan-Russo Communications, Inc., 212-696-4455/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU:

SM-TM -- NY062 -- 5188 08/23/93 16:56 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 23, 1993
Words:154
Previous Article:INNOVATIVE GAMING ANNOUNCES FENTZ HIRED AS CHIEF OPERATING OFFICER
Next Article:AMERICAN STOCK EXCHANGE DAILY REPORT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters